)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Devyser Diagnostics
Devyser Diagnostics (DVYSR) investor relations material
Devyser Diagnostics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
Q3 net sales rose 5.8% YoY to SEK 59.7m; FX-adjusted growth was 5.7%. A major distributor’s inventory correction continued to constrain sales.
Q3 EBIT improved to SEK 7.1m from SEK 1.3m; net profit was SEK 7.3m versus a SEK 2.8m loss, and operating cash flow was SEK 22.0m.
Underlying demand remained strong, particularly in direct markets; distributor sales are expected to remain weaker through Q4 before normalizing from 2027.
Financial highlights
9M net sales were SEK 181.7m, up 1.8% reported and 4.9% FX-adjusted; 9M gross profit was SEK 145.8m versus SEK 144.7m.
9M EBIT was SEK 10.2m versus a SEK 8.0m loss; net profit was SEK 11.8m versus a SEK 22.0m loss, and EPS was SEK 0.70 versus a SEK 1.33 loss.
Q3 EBITDA was SEK 14.7m with a 24.6% margin, versus SEK 8.1m and 14.4%; Q3 EPS was SEK 0.43 versus a SEK 0.17 loss.
Q3 selling expenses fell to SEK 23.6m from SEK 26.2m; 9M operating expenses declined to SEK 136.5m from SEK 152.3m, mainly from cost-efficiency measures.
Operating cash flow was SEK 22.0m versus negative SEK 0.5m; liquidity was SEK 88.7m versus SEK 84.9m.
Outlook and guidance
Distributor sales are expected to remain weaker through Q4 due to inventory reduction, with a gradual return to more normal levels during 2027; quarterly timing remains uncertain.
The aim is profitable growth faster than the market, prioritizing the US and Western Europe while maintaining cost efficiency.
A MolDx decision is targeted before year-end, subject to review timing; FDA work, commercialization preparations, channel strategy and IVDR certification continue.
Reagent rental agreements are expected to contribute more visibly to growth in 2027; sales may begin after system installation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Devyser Diagnostics
- Rapid growth, global expansion, and innovation drive leadership in decentralized diagnostics.DVYSR
Life Science Conference 2026 - Q2 sales dropped 10.7% as distributor inventory rose, but EBIT stayed positive and growth is expected.DVYSRQ2 2026
- Q1 net sales up 12.9%, EBIT positive, with Cybergene and Illumina deals driving future growth.DVYSRQ1 2026
- Record sales and EBIT turnaround driven by growth, innovation, and strategic partnerships.DVYSRQ4 2025
- FDA approval for Accept cfDNA could transform US transplant diagnostics and drive growth.DVYSRCMD 2024
- Q3 sales up 4.4%, gross margin down to 72%, and China approval drives future growth.DVYSRQ3 2024
- Q2 sales up 41%, global expansion and margin recovery expected by year-end.DVYSRQ2 2024
- Revenue up 7.9% YoY to SEK 54.8m, gross margin 83.4%, and major tenders drive outlook.DVYSRQ1 2025
- First profitable quarter with record sales and strong growth momentum globally.DVYSRQ4 2024
Next Devyser Diagnostics earnings date
Q4 202616 Feb, 2027
Devyser Diagnostics
Next Devyser Diagnostics earnings date
Q4 202616 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Devyser Diagnostics AB is a Swedish company that develops, manufactures, and sells advanced diagnostic kits for DNA testing. Their products are primarily used in the fields of hereditary diseases, oncology, and post-transplantation monitoring. These diagnostic solutions enable laboratories to conduct complex genetic tests, including those for cancer treatments, prenatal screening, and transplant patient follow-ups. The company also provides software tools for data analysis and interpretation to support their test kits. The company is headquartered in Stockholm, Sweden, and its shares are traded on the Nasdaq Stockholm.